These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34142274)

  • 1. Preferences for Current and Future PrEP Modalities Among PrEP-Experienced Gay and Bisexual Men in Australia.
    Chan C; Vaccher S; Fraser D; Grulich AE; Holt M; Zablotska-Manos I; Prestage GP; Bavinton BR
    AIDS Behav; 2022 Jan; 26(1):88-95. PubMed ID: 34142274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.
    Hsu JH; Ku SW; Chen TW; Li CW; Huang P; Wu HJ; Bourne A; Strong C
    J Int AIDS Soc; 2023 Sep; 26(9):e26163. PubMed ID: 37675767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.
    Mansergh G; Kota KK; Stephenson R; Hirshfield S; Sullivan P
    J Int AIDS Soc; 2021 Jan; 24(1):e25664. PubMed ID: 33481359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex With Men.
    Tran NK; Martinez O; Scheim AI; Goldstein ND; Welles SL
    AIDS Educ Prev; 2022 Oct; 34(5):365-378. PubMed ID: 36181495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferences Across Pre-Exposure Prophylaxis Modalities Among Young Men Who Have Sex with Men in the United States: A Latent Class Analysis Study.
    Valente PK; Bauermeister JA; Lin WY; Silva DTD; Hightow-Weidman L; Drab R; Mayer KH; Operario D; Rusley J; Biello KB
    AIDS Patient Care STDS; 2022 Nov; 36(11):431-442. PubMed ID: 36367995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
    Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
    J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.
    Liu Y; Chu Z; Wang H; Huang X; Chen Y; Wang H; Zou D; Jiang Y; Geng W; Hu Q; Zhou B; Shang H
    BMC Public Health; 2023 Dec; 23(1):2494. PubMed ID: 38093204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men.
    Dean LT; Predmore Z; Skinner A; Napoleon S; Chan PA; Raifman J
    AIDS Behav; 2023 Aug; 27(8):2606-2616. PubMed ID: 36670210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injectable Pre-Exposure Prophylaxis for HIV Prevention: Perspectives on the Benefits and Barriers from Gay, Bisexual, and Queer Men and Health System Stakeholders in Ontario, Canada.
    Grace D; Gaspar M; Wells A; Sinno J; Daroya E; Montess M; Hull M; Lachowsky NJ; Tan DHS
    AIDS Patient Care STDS; 2023 Jun; 37(6):306-315. PubMed ID: 37195728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa.
    Ogunbajo A; Tsai AC; Kanki PJ; Mayer KH
    AIDS Behav; 2022 Jul; 26(7):2363-2375. PubMed ID: 35061117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated With Willingness to Use Daily Antibiotics as Sexually Transmitted Infection Prophylaxis Among HIV Preexposure Prophylaxis-Experienced Gay and Bisexual Men in Australia.
    Arapali T; Grulich AE; Heywood AE; Chan C; Fraser D; Zablotska IB; Holt M; Vaccher SJ; Bavinton BR
    Sex Transm Dis; 2023 Mar; 50(3):144-149. PubMed ID: 36730780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.
    Schoenberg P; Edwards OW; Merrill L; Martinez CA; Stephenson R; Sullivan PS; Jones J
    J Int AIDS Soc; 2023 Mar; 26(3):e26077. PubMed ID: 36951057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
    Parsons JT; Rendina HJ; Whitfield TH; Grov C
    AIDS Behav; 2016 Jul; 20(7):1390-9. PubMed ID: 27000145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
    John SA; Whitfield THF; Rendina HJ; Parsons JT; Grov C
    AIDS Behav; 2018 Apr; 22(4):1184-1189. PubMed ID: 28913659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among Young Adult Sexual Minority Men and Transgender Women.
    Weeden T; Garofalo R; Johnson AK; Schnall R; Cervantes M; Scherr T; Kuhns LM
    Acad Pediatr; 2024; 24(7):1110-1115. PubMed ID: 38631476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience.
    Meyers K; Wu Y; Brill A; Sandfort T; Golub SA
    PLoS One; 2018; 13(7):e0200296. PubMed ID: 30024903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Daily and On-Demand Oral Pre-Exposure Prophylaxis Dosing Strategies Among Young Adult Gay, Bisexual and Other Men who have Sex with Men Enrolled in an mHealth Adherence Intervention.
    Horvath KJ; Ma J; Storholm ED; Black A; Klaphake J; Baker JV
    AIDS Behav; 2023 Nov; 27(11):3632-3644. PubMed ID: 37195471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old.
    John SA; Zapata JP; Dang M; Pleuhs B; O'Neil A; Hirshfield S; Walsh JL; Petroll AE; Quinn KG
    Sci Rep; 2023 Mar; 13(1):5116. PubMed ID: 36991027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferences for Long-Acting and Alternative Modalities for PrEP among Military Men Who Have Sex with Men: Segmentation Results of an Adaptive Choice-Based Conjoint Analysis Study.
    Gutierrez JI; Vlahov D; Dubov A; Altice FL
    J Urban Health; 2022 Apr; 99(2):277-292. PubMed ID: 35318573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.